<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="with the cytokine storm in severe cases and use of" exact="tocilizumab" post="has shown good outcomes in a small cohort. Baricitinib"/>
 <result pre="commonly used immunosuppressive drugs such as JAK kinase inhibitors and" exact="tocilizumab" post="have been proposed and/or used for the treatment of"/>
 <result pre="that hydroxychloroquine, which shares the same mechanism of action as" exact="chloroquine" post="but has a better safety profile and is frequently"/>
 <result pre="connective tissue disease, has a more potent anti-viral effect than" exact="chloroquine" post="in vitro. From the results of physiologically-based pharmacokinetic models,"/>
 <result pre="daily for four days reaches three times the potency of" exact="chloroquine" post="and is therefore a promising drug for both the"/>
 <result pre="clinical trials that are ongoing to study the efficacy of" exact="chloroquine" post="or hydroxychloroquine in CoViD-19 patients. Hydroxychloroquine is thus being"/>
 <result pre="that are ongoing to study the efficacy of chloroquine or" exact="hydroxychloroquine" post="in CoViD-19 patients. Hydroxychloroquine is thus being used in"/>
 <result pre="or life-threatening cytokine release syndrome [12]. A single dose of" exact="tocilizumab" post="was used in 21 patients in China suffering from"/>
 <result pre="with crowded places. Smart working is encouraged. 3- Chloroquine and" exact="hydroxychloroquine" post="seem to have some efficacy on SARS-CoV2 infection. 4-"/>
 <result pre="biologic drugs, must be guaranteed for rheumatic patients. This includes" exact="tocilizumab" post="and baricitinib availability for patients chronically taking these compounds,"/>
 <result pre="biologic therapies which are available only in some hospitals. As" exact="tocilizumab" post="and baricitinib may start to be used to treat"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="monocyte-derived macrophages and dendritic cellsJ. Virol.837200930393048Epub 2008/11/1219004938 12LeR.Q.LiL.YuanW.ShordS.S.NieL.HabtemariamB.A.FDA approval summary:" exact="tocilizumab" post="for treatment of chimeric antigen receptor T cell-induced severe"/>
</results>
